FDA Grants Accelerated Approval to Olaratumab for Treatment of Advanced Soft-Tissue Sarcoma

The U.S. Food and Drug Administration (FDA) granted accelerated approval to olaratumab in combination with doxorubicin to treat adults with certain types of soft-tissue sarcoma...


Using Watson to Analyze Genomic Data to Personalize Treatment for Patients With Cancer

Three years ago, IBM’s Watson supercomputer was best known for defeating two former champions on the TV game show Jeopardy! Today, it is grabbing headlines for...

Gynecologic Cancers
Issues in Oncology

The FDA Urges Physicians and Patients to Forgo Ovarian Cancer Screening Tests

In a Safety Communication directed at women and physicians, the U.S. Food and Drug Administration (FDA) alerted women “about the risks associated with the use of tests...


More Top Stories

Skin Cancer

Paolo A. Ascierto, MD, on Metastatic Melanoma: Ipilimumab Study Results

Issues in Oncology
Health-Care Policy

Why Curing Cancer Will Take Decades

This past summer, Eric S. Lander, PhD, President of the Broad Institute of the Massachusetts Institute of Technology and Harvard in Cambridge, Massachusetts, and Co-Chair of the President’s Council of Advisors on Science and Technology, raised a few eyebrows at the Aspen Ideas Festival when he...


Study Finds Nivolumab Improves Survival vs Standard Therapy in Recurrent Squamous Cell Carcinoma of the Head and Neck

In the phase III CheckMate 141 trial reported in The New England Journal of Medicine, Ferris et al found that nivolumab (Opdivo) increased overall survival vs standard therapies in patients with recurrent platinum-refractory squamous cell carcinoma of the head and neck.

Study Details

In this...


Teresa Calimeri, MD, PhD, on DLBCL: Findings on High-Dose Methotrexate (Italian Language Version)

Hematologic Malignancies

Update on Neoplastic Hematology: Review of Recent Clinical Trials

Here is a brief look at the study findings and clinical implications of several recent clinical trials on newer treatment options in neoplastic hematology. Attention is focused on several types of leukemia, Hodgkin lymphoma, and multiple myeloma.


Clinical Trial: INO-VATE ALL phase III...

ASCO International Course Helps Ethiopia Realize Its Goal of Improving Cancer Care

Ethiopia, similar to other African countries, has a significant shortage of physicians. Currently, there are 0.3 physicians for every 100,000 people, a rate that is substantially lower than the 2 physicians per 100,000 people found in the rest of Africa. This year, the First Lady of Ethiopia,...

Investigational Immunotherapy Appears Safe and Somewhat Active in Advanced Melanoma

The investigational immunotherapeutic IMC-20D7S was found to be well tolerated and somewhat active in patients with advanced melanoma, including one complete response, according to the results of a phase I/Ib trial reported by Khalil et al in Clinical Cancer Research. 

IMD-20D7S is a...

Prostate Cancer

Christopher J. Sweeney, MBBS, on Prostate Cancer: CHAARTED Trial Follow-Up

Gynecologic Cancers

Risk of Serous/Serous-like Endometrial Carcinoma After RRSO in Women With BRCA1 Mutation

In a prospective cohort study reported in JAMA Oncology, Shu et al found that risk for serous/serous-like endometrial carcinoma appeared to be increased after risk-reducing salpingo-oophorectomy (RRSO) without hysterectomy in women harboring the BRCA1 mutation. The overall risk of uterine cancer...


ESMO 2016: Clinical Benefit Demonstrated With Everolimus and Pasireotide LAR Alone or in Combination in Advanced Lung and Thymic Carcinoids

In patients with advanced lung or thymus carcinoid receiving everolimus, pasireotide LAR, or the combination of the two drugs, statistically significant positive impact was seen on proportion of patients’ progression-free rate at 9 months (primary endpoint) in all three arms, more relevant in ...

click me